Welcoming Maria Rizzo to GIPAM – Advancing Evidence Synthesis Through Exclusive Partnership
We are excited to announce an exclusive partnership with Maria Rizzo, a leader in evidence synthesis and software development, who will play a pivotal role in expanding our evidence synthesis offering, and enhancing, our proprietary literature review tool, ANCHOR.
With over 18 years of experience, Maria’s career began with systematic literature reviews and meta-analyses for the National Institute for Health and Care Excellence (NICE). She has since held global HEOR roles at Evidera and Cencora, supporting evidence generation for HTA submissions. Most recently, as Vice President of Evidence Review and Software at Cytel, she expanded the development and commercialization of LiveSLR®, a literature review platform.
Driving Innovation in Evidence Synthesis
Through this exclusive partnership, Maria will work closely with GIPAM to expand our evidence synthesis capabilities and optimise ANCHOR—helping clients navigate complex pre- and post-market access challenges with confidence.
Her leadership in systematic reviews, meta-analyses, and software innovation aligns perfectly with GIPAM’s vision to deliver robust, efficient, and impactful HEOR solutions. By combining expertise in evidence synthesis, AI-driven automation, and software development, we are taking a significant step forward in shaping the future of evidence generation.
A Stronger Future with ANCHOR
This collaboration reinforces GIPAM’s mission to elevate the standard for literature reviews and enhance our offerings for HTA submissions, real-world evidence, and health economic modelling. With Maria’s expertise, ANCHOR will become an even more powerful tool, ensuring smarter, faster, and more reliable evidence generation for our clients.
We are thrilled to welcome Maria and look forward to this exciting new chapter! Watch as Maria Rizzo and Thomas Wilke discuss this exclusive partnership and what it means for evidence synthesis at GIPAM.
Want to learn more about our work in evidence synthesis? Get in touch to explore how we can support your market access strategy.